TCF-001 TRACK (Target Rare Cancer Knowledge) Study
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
| Condition(s) | Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results. |
| Who can participate | INCLUSION CRITERIA * Provision of signed and dated informed consent form. * Stated willingness to comply with all study related blood draws and assessments for the duration of the study. * Individuals who are 18 years old or older at the time of consent. * Patients with a rare (fewer than 6 cases per 100,000 per year) solid tumor or lymphoma with evaluable disease at baseline. The complete list of included cancers are included in the study protocol; diseases not listed in the study protocol may be enrolled with the approval of the Principal Investigator. * May or may not have had qualifying (by Foundation Medicine) comprehensive genomic profiling before the present study. For those who have had qualifying comprehensive genomic profiling performed prior to the present study, the archival sp |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | TargetCancer Foundation |
| Locations | Cambridge, Massachusetts, United States |
| Start date | 2020-10-01 |
| NCT ID | NCT04504604 |
| Official listing | https://clinicaltrials.gov/study/NCT04504604 |